Hudson Bay Capital Management
RLMD icon

Hudson Bay Capital Management’s Relmada Therapeutics RLMD Stock Holding History

Hudson Bay Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-42,141
Closed -$293K – 1638
2026
Q1 		$293K Buy
42,141
+15,894
+61% +$75.2K ﹤0.01% 1036
2025
Q4 		$127K Buy
+26,247
New +$87.9K ﹤0.01% 1001

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Hudson Bay Capital Management's RLMD Position: Q2 2026 in Review

Hudson Bay Capital Management sold out of Relmada Therapeutics (RLMD) in Q2 2026, closing a stake of 42,141 shares — an estimated $293K sold.

Hudson Bay Capital Management first reported a position in RLMD in Q4 2025 and held it in 2 quarters. The position peaked at $293K in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Hudson Bay Capital Management reported no remaining Relmada Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 42,141 Relmada Therapeutics shares in Q2 2026, an estimated $293K.
  • Hudson Bay Capital Management first reported a position in Relmada Therapeutics in Q4 2025 and held it in 2 quarters.
  • Hudson Bay Capital Management's Relmada Therapeutics position peaked at $293K in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.